Olanzapine long-acting injection: a review of first experiences of post-injection delirium/sedation syndrome in routine clinical practice
Open Access
- 2 April 2015
- journal article
- review article
- Published by Springer Nature in BMC Psychiatry
- Vol. 15 (1) , 65
Abstract
Olanzapine long-acting injection (LAI) for the treatment of schizophrenia was associated with a cluster of symptoms termed post-injection delirium/sedation syndrome (PDSS) in a small percentage (~2%) of patients during clinical trials. The objective of this analysis was to evaluate the rate and clinical characteristics of PDSS since olanzapine LAI entered commercial use. Cases of PDSS were identified from all reported adverse events during worldwide commercial use of olanzapine LAI through to 1 March 2014. Data sources included two ongoing post-marketing safety studies as well as spontaneously reported adverse events from routine clinical practice over a 5-year period (1 March 2009 to 1 March 2014). A total of 338 PDSS events were identified. Of these, 91% occurred within 1 hour of injection, and 52% of these occurred within 15 minutes. None of the PDSS events in this analysis were fatal, and most resolved within 72 hours. The most common symptoms (occurring in >30% of cases) were sedation (61%), confusion (56%), dysarthria (54%), somnolence (46%), dizziness (45%) and disorientation (35%). Overall, PDSS occurred with approximately 0.07% of injections and in 0.46–1.03% of patients (reporting and incidence rates from spontaneous reports and post-marketing safety studies, respectively). The PDSS events reported during routine clinical use of olanzapine LAI are generally similar in incidence and presentation to those reported in clinical trials. Caution should be applied when interpreting spontaneously reported rates of adverse events, however, due to potential under-reporting. Implemented risk-minimisation activities may contribute substantially to the identification and appropriate management of patients with PDSS in clinical practice.Keywords
This publication has 14 references indexed in Scilit:
- The time-dependant post-mortem redistribution of antipsychotic drugsForensic Science International, 2012
- Long-Term Safety and Tolerability of Open-Label Olanzapine Long-Acting Injection in the Treatment of Schizophrenia: 190-Week Interim ResultsClinical Medicine Insights: Psychiatry, 2011
- Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanismBMC Psychiatry, 2010
- Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of casesBMC Psychiatry, 2010
- Olanzapine Long-Acting Injection: A 24-Week, Randomized, Double-Blind Trial of Maintenance Treatment in Patients With SchizophreniaAmerican Journal of Psychiatry, 2010
- Fatal toxicity of drugs used in psychiatryHuman Psychopharmacology: Clinical and Experimental, 2007
- Complications After Unintentional Intra-arterial Injection of Drugs: Risks, Outcomes, and Management StrategiesMayo Clinic Proceedings, 2005
- Adverse drug event monitoring at the food and drug administrationJournal of General Internal Medicine, 2003
- Delusions Induced by Procaine Penicillin: Case Report and Review of the SyndromeThe International Journal of Psychiatry in Medicine, 1987
- Systemic Toxic Reactions to Procaine Penicillin GSexually Transmitted Diseases, 1978